Correlation Between Revelation Biosciences and CytomX Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Revelation Biosciences and CytomX Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Revelation Biosciences and CytomX Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Revelation Biosciences and CytomX Therapeutics, you can compare the effects of market volatilities on Revelation Biosciences and CytomX Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Revelation Biosciences with a short position of CytomX Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Revelation Biosciences and CytomX Therapeutics.

Diversification Opportunities for Revelation Biosciences and CytomX Therapeutics

0.48
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Revelation and CytomX is 0.48. Overlapping area represents the amount of risk that can be diversified away by holding Revelation Biosciences and CytomX Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytomX Therapeutics and Revelation Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Revelation Biosciences are associated (or correlated) with CytomX Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytomX Therapeutics has no effect on the direction of Revelation Biosciences i.e., Revelation Biosciences and CytomX Therapeutics go up and down completely randomly.

Pair Corralation between Revelation Biosciences and CytomX Therapeutics

Given the investment horizon of 90 days Revelation Biosciences is expected to generate 2.1 times more return on investment than CytomX Therapeutics. However, Revelation Biosciences is 2.1 times more volatile than CytomX Therapeutics. It trades about -0.1 of its potential returns per unit of risk. CytomX Therapeutics is currently generating about -0.24 per unit of risk. If you would invest  752.00  in Revelation Biosciences on December 4, 2024 and sell it today you would lose (406.51) from holding Revelation Biosciences or give up 54.06% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Revelation Biosciences  vs.  CytomX Therapeutics

 Performance 
       Timeline  
Revelation Biosciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Revelation Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
CytomX Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Revelation Biosciences and CytomX Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Revelation Biosciences and CytomX Therapeutics

The main advantage of trading using opposite Revelation Biosciences and CytomX Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Revelation Biosciences position performs unexpectedly, CytomX Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will offset losses from the drop in CytomX Therapeutics' long position.
The idea behind Revelation Biosciences and CytomX Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm